Gene Therapy Production Must Pass Regulatory Hurdles

August 1, 2019

Mass-produce cell and gene therapies presents the biopharma industry with a unique set of challenges.

While researchers are succeeding with developing cell therapies and gene therapies, bringing technologies and processes to mass-produce the treatments, in an emerging and regulated environment, presents the biopharma industry with a unique set of challenges, says Eric Langer, managing partner, BioPlan Associates, in an interview with BioPharm International.